These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 16203809)

  • 1. Determining maximal tolerable dose of the monoclonal antibody BR96 labeled with 90Y or 177Lu in rats: establishment of a syngeneic tumor model to evaluate means to improve radioimmunotherapy.
    Mårtensson L; Wang Z; Nilsson R; Ohlsson T; Senter P; Sjögren HO; Strand SE; Tennvall J
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7104s-7108s. PubMed ID: 16203809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequential radioimmunotherapy with 177Lu- and 211At-labeled monoclonal antibody BR96 in a syngeneic rat colon carcinoma model.
    Eriksson SE; Elgström E; Bäck T; Ohlsson T; Jensen H; Nilsson R; Lindegren S; Tennvall J
    Cancer Biother Radiopharm; 2014 Aug; 29(6):238-46. PubMed ID: 24971673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment with unlabeled mAb BR96 after radioimmunotherapy with 177Lu-DOTA-BR96 in a syngeneic rat colon carcinoma model.
    Eriksson SE; Ohlsson T; Nilsson R; Tennvall J
    Cancer Biother Radiopharm; 2012 Apr; 27(3):175-82. PubMed ID: 22417248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repeated radioimmunotherapy with 177Lu-DOTA-BR96 in a syngeneic rat colon carcinoma model.
    Eriksson SE; Ohlsson T; Nilsson R; Tennvall J
    Cancer Biother Radiopharm; 2012 Mar; 27(2):134-40. PubMed ID: 22229635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radioimmunotherapy of prostate cancer using 90Y- and 177Lu-labeled J591 monoclonal antibodies: effect of multiple treatments on myelotoxicity.
    Vallabhajosula S; Goldsmith SJ; Kostakoglu L; Milowsky MI; Nanus DM; Bander NH
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7195s-7200s. PubMed ID: 16203821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative efficacy of 177Lu and 90Y for anti-CD20 pretargeted radioimmunotherapy in murine lymphoma xenograft models.
    Frost SH; Frayo SL; Miller BW; Orozco JJ; Booth GC; Hylarides MD; Lin Y; Green DJ; Gopal AK; Pagel JM; Bäck TA; Fisher DR; Press OW
    PLoS One; 2015; 10(3):e0120561. PubMed ID: 25785845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose radioimmunotherapy combined with extracorporeal depletion in a syngeneic rat tumor model: evaluation of toxicity, therapeutic effect, and tumor model.
    Mårtensson L; Nilsson R; Ohlsson T; Sjögren HO; Strand SE; Tennvall J
    Cancer; 2010 Feb; 116(4 Suppl):1043-52. PubMed ID: 20127949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The intratumoral distribution of radiolabeled 177Lu-BR96 monoclonal antibodies changes in relation to tumor histology over time in a syngeneic rat colon carcinoma model.
    Örbom A; Eriksson SE; Elgström E; Ohlsson T; Nilsson R; Tennvall J; Strand SE
    J Nucl Med; 2013 Aug; 54(8):1404-10. PubMed ID: 23804328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiation absorbed dose estimation for 90Y-DOTA-biotin with pretargeted NR-LU-10/streptavidin.
    Breitz HB; Fisher DR; Goris ML; Knox S; Ratliff B; Murtha AD; Weiden PL
    Cancer Biother Radiopharm; 1999 Oct; 14(5):381-95. PubMed ID: 10850323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different toxicity profiles for drug- versus radionuclide-conjugated BR96 monoclonal antibodies in a syngeneic rat colon carcinoma model.
    Nilsson R; Eriksson SE; Sjögren HO; Tennvall J
    Acta Oncol; 2011 Jun; 50(5):711-8. PubMed ID: 21214493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
    Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
    Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
    Wong JYC ; Chu DZ; Yamauchi DM; Williams LE; Liu A; Wilczynski S; Wu AM; Shively JE; Doroshow JH; Raubitschek AA
    Clin Cancer Res; 2000 Oct; 6(10):3855-63. PubMed ID: 11051230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Three-step radioimmunotherapy with yttrium-90 biotin: dosimetry and pharmacokinetics in cancer patients.
    Cremonesi M; Ferrari M; Chinol M; Stabin MG; Grana C; Prisco G; Robertson C; Tosi G; Paganelli G
    Eur J Nucl Med; 1999 Feb; 26(2):110-20. PubMed ID: 9933344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimizing lutetium 177-anti-carbonic anhydrase IX radioimmunotherapy in an intraperitoneal clear cell renal cell carcinoma xenograft model.
    Muselaers CH; Oosterwijk E; Bos DL; Oyen WJ; Mulders PF; Boerman OC
    Mol Imaging; 2014; 13():1-7. PubMed ID: 24824962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blood pharmacokinetics of various monoclonal antibodies labeled with a new trifunctional chelating reagent for simultaneous conjugation with 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid and biotin before radiolabeling.
    Wang Z; Mårtensson L; Nilsson R; Bendahl PO; Lindgren L; Ohlsson T; Sjögren HO; Strand SE; Tennvall J
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7171s-7177s. PubMed ID: 16203818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?
    Sharkey RM; Brenner A; Burton J; Hajjar G; Toder SP; Alavi A; Matthies A; Tsai DE; Schuster SJ; Stadtmauer EA; Czuczman MS; Lamonica D; Kraeber-Bodere F; Mahe B; Chatal JF; Rogatko A; Mardirrosian G; Goldenberg DM
    J Nucl Med; 2003 Dec; 44(12):2000-18. PubMed ID: 14660727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin.
    Koppe MJ; Bleichrodt RP; Soede AC; Verhofstad AA; Goldenberg DM; Oyen WJ; Boerman OC
    J Nucl Med; 2004 Jul; 45(7):1224-32. PubMed ID: 15235070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biodistribution and preclinical radioimmunotherapy studies using radiolanthanide-labeled immunoconjugates.
    Schott ME; Schlom J; Siler K; Milenic DE; Eggensperger D; Colcher D; Cheng R; Kruper WJ; Fordyce W; Goeckeler W
    Cancer; 1994 Feb; 73(3 Suppl):993-8. PubMed ID: 8306291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radioimmunotherapy of a human lung cancer xenograft with monoclonal antibody RS7: evaluation of (177)Lu and comparison of its efficacy with that of (90)Y and residualizing (131)I.
    Stein R; Govindan SV; Chen S; Reed L; Richel H; Griffiths GL; Hansen HJ; Goldenberg DM
    J Nucl Med; 2001 Jun; 42(6):967-74. PubMed ID: 11390564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of Monte Carlo simulations with a realistic rat phantom for examining the correlation between hematopoietic system response and red marrow absorbed dose in Brown Norway rats undergoing radionuclide therapy with (177)Lu- and (90)Y-BR96 mAbs.
    Larsson E; Ljungberg M; Martensson L; Nilsson R; Tennvall J; Strand SE; Jonsson BA
    Med Phys; 2012 Jul; 39(7):4434-43. PubMed ID: 22830776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.